Disitamab vedotin

Names

[ Name ]:
Disitamab vedotin

Biological Activity

[Description]:

Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent monomethyl auristatin E. Disitamab vedotin enhances antitumor immunity[1].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> JAK/STAT Signaling >> EGFR

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> EGFR

[Target]

HER2

[In Vitro]

The antibody part was a humanized monoclonal antibody targeting HER2, the small molecule toxin was monomethyl auristatin E (MMAE), a synthetic antineoplastic agent. A protease cleavable linker covalently attached MMAE to the antibody[2].

[References]

[1]. Deeks ED. Disitamab Vedotin: First Approval. Drugs. 2021;81(16):1929-1935.

[2]. Jiang J, et al. Preclinical safety profile of disitamab vedotin：a novel anti-HER2 antibody conjugated with MMAE. Toxicol Lett. 2020;324:30-37.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.